Stroke RSS

Filtered By:
Source: Circulation
Condition: Ischemic Stroke
Therapy: Statin Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
CONCLUSIONS: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACEs increased across baseline apoB strata. Alirocumab reduced MACEs across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACEs, even after accounting for achieved low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of an apoB level ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrom...
Source: Circulation - June 30, 2022 Category: Cardiology Authors: Emil Hagstr öm P Gabriel Steg Michael Szarek Deepak L Bhatt Vera A Bittner Nicolas Danchin Rafael Diaz Shaun G Goodman Robert A Harrington J Wouter Jukema Evangelos Liberopoulos Nikolaus Marx Jennifer McGinniss Garen Manvelian Robert Pordy Michel Scemama Source Type: research

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG
Conclusions: In REDUCE-IT patients with a history of CABG, treatment with icosapent ethyl was associated with significant reductions in first and recurrent ischemic events.PMID:34710343 | DOI:10.1161/CIRCULATIONAHA.121.056290
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Subodh Verma Deepak L Bhatt Ph Gabriel Steg Michael Miller Eliot A Brinton Terry A Jacobson Nitish K Dhingra Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz C Michael Gibson Duane Pinto Robert P Giugliano Matthew J Budoff R Pre Source Type: research

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01492361.PMID:34706555 | DOI:10.1161/CIRCULATIONAHA.121.055560
Source: Circulation - October 28, 2021 Category: Cardiology Authors: Arjun Majithia Deepak L Bhatt Allon N Friedman Michael Miller Ph Gabriel Steg Eliot A Brinton Terry A Jacobson Steven B Ketchum Rebecca A Juliano Lixia Jiao Ralph T Doyle Craig Granowitz Matthew Budoff R Preston Mason Jean-Claude Tardif William E Boden Ch Source Type: research

Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Conclusions: After accounting for differences in baseline characteristics and adherence, patients treated with alirocumab who achieved LDL-C levels <25 mg/dL did not appear to derive further reduction in the risk of MACE compared to those who achieved LDL-C levels of 25-50 mg/dL. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier: NCT01663402. PMID: 33438437 [PubMed - as supplied by publisher]
Source: Circulation - January 13, 2021 Category: Cardiology Authors: Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M, ODYSSEY OUTCOMES Committees and Investigators Tags: Circulation Source Type: research

Temporal Changes in Secondary Prevention and Cardiovascular Outcomes after Revascularization for Peripheral Arterial Disease in Denmark: A Nationwide Cohort Study.
Conclusions: Medical prevention of adverse events has increased considerably over time in patients that underwent revascularization for symptomatic PAD. This increase was accompanied by reductions in all adverse outcomes, except major amputations. PMID: 33300375 [PubMed - as supplied by publisher]
Source: Circulation - December 10, 2020 Category: Cardiology Authors: Søgaard M, Nielsen PB, Skjøth F, Eldrup N, Larsen TB Tags: Circulation Source Type: research

Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque.
Conclusions: Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis. Optimization of cardiovascular risk factors and increased awareness of cardiovascular risk, prior to, during and after treatment, should be considered among patients on an ICI. PMID: 33003973 [PubMed - as supplied by publisher]
Source: Circulation - October 1, 2020 Category: Cardiology Authors: Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG Tags: Circulation Source Type: research

Carotid Atherosclerosis Evolution when Targeting a Low-Density Lipoprotein Cholesterol Concentration < 70 mg/dL after an Ischemic Stroke of Atherosclerotic Origin.
Conclusions: In patients with ischemic stroke and atherosclerosis, an LDL-C target of <70 mg/dL (1.8 mmol/L) did not reduce the incidence of new carotid plaques but produced significantly greater regression of carotid atherosclerosis than an LDL-C target of 90 to 110 mg/dL. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01252875. PMID: 32594766 [PubMed - as supplied by publisher]
Source: Circulation - June 28, 2020 Category: Cardiology Authors: Amarenco P, Hobeanu C, Labreuche J, Charles H, Giroud M, Meseguer E, Lavallée PC, Steg PG, Vicaut É, Bruckert E, Touboul PJ Tags: Circulation Source Type: research

Impact of ADCY9 Genotype on Response to Anacetrapib.
CONCLUSIONS: The REVEAL trial is the single largest study to date evaluating the ADCY9 pharmacogenetic interaction. It provides no support for the hypothesis that ADCY9 genotype is materially relevant to the clinical effects of the CETP inhibitor anacetrapib. The ongoing dal-GenE study will provide direct evidence as to whether there is any specific pharmacogenetic interaction with dalcetrapib. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov Unique Identifier: NCT01252953; URL: http://www.isrctn.com Unique Identifier: ISRCTN48678192; URL: https://www.clinicaltrialsregister.eu Unique Identifier: 2010-0...
Source: Circulation - July 22, 2019 Category: Cardiology Authors: Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, Collins R, HPS3/TIMI55 - REVEAL Collaborative Group Tags: Circulation Source Type: research

Acute Limb Ischemia in Peripheral Artery Disease: Insights from EUCLID.
CONCLUSIONS: Prior peripheral revascularization, baseline atrial fibrillation, and lower ABI identify PAD patients at heightened risk for ALI, an event associated with subsequent cardiovascular and limb-related morbidity and mortality. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT01732822. PMID: 31238713 [PubMed - as supplied by publisher]
Source: Circulation - June 25, 2019 Category: Cardiology Authors: Hess CN, Huang Z, Patel MR, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Held P, Jones WS, Katona B, Mahaffey KW, Norgren L, Rockhold FW, Hiatt WR Tags: Circulation Source Type: research

Pages: 1 2